Английская Википедия:BTRX-246040

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD).[1][2][3] It has demonstrated proof-of-concept clinical efficacy for depression.[4] As of 2017, it is in phase II clinical trials for the treatment of MDD.[1][2][3] It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued.[1]

See also

References

Шаблон:Reflist

External links

Шаблон:Opioid receptor modulators

Шаблон:Nervous-system-drug-stub